[1]
|
Parker AL,Kavallaris M,McCarroll JA.Microtubules and their role in cellular stress in cancer[J].Front Oncol,2014,4:153. |
[2]
|
Prosser SL,Pelletier L.Mitotic spindle assembly in animal cells: a fine balancing act[J].Nat Rev Mol Cell Biol,2017,18(3):187-201. |
[3]
|
Jordan MA,Wilson L.Microtubules as a target for anticancer drugs[J].Nat Rev Cancer,2004,4(4):253-265. |
[4]
|
Li W,Zhang H,Assaraf YG,et al.Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies[J].Drug Resist Updat,2016,27:14-29. |
[5]
|
Krishna R,Mayer LD.Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J].Eur J Pharm Sci,2000,11(4):265-283. |
[6]
|
Hao XY,Widersten M,Ridderstrom M,et al.Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme[J].Biochem J,1994,297 (Pt 1):59-67. |
[7]
|
Ogiso Y,Tomida A,Tsuruo T.Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase Ⅱ-directed drugs[J].Cancer Res,2002,62(17):5008-5012. |
[8]
|
Fernald K,Kurokawa M.Evading apoptosis in cancer[J].Trends Cell Biol,2013,23(12):620-633. |
[9]
|
Krauze A,Grinberga S,Krasnova L,et al.Thieno[2,3-b]pyridines——a new class of multidrug resistance (MDR) modulators[J].Bioorg Med Chem,2014,22(21):5860-5870. |
[10]
|
Dostal V,Libusova L.Microtubule drugs: action, selectivity, and resistance across the kingdoms of life[J].Protoplasma,2014,251(5):991-1005. |
[11]
|
Hu T,Li Z,Gao CY,et al.Mechanisms of drug resistance in colon cancer and its therapeutic strategies[J].World J Gastroenterol,2016,22(30):6876-6889. |
[12]
|
Kavallaris M.Microtubules and resistance to tubulin-binding agents[J].Nat Rev Cancer,2010,10(3):194-204. |
[13]
|
Kavallaris M,Annereau JP,Barret JM.Potential mechanisms of resistance to microtubule inhibitors[J].Semin Oncol,2008,35(3 Suppl 3):S22-S27. |
[14]
|
Gan PP,Pasquier E,Kavallaris M.Class Ⅲ beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer[J].Cancer Res,2007,67(19):9356-9363. |
[15]
|
Amos LA.What tubulin drugs tell us about microtubule structure and dynamics[J].Semin Cell Dev Biol,2011,22(9):916-926. |
[16]
|
Löwe J,Li H,Downing KH,et al.Refined structure of αβ-tubulin at 3.5 Å resolution[J].J Mol Biol,2001,313(5):1045-1057. |
[17]
|
Devambatla RK,Namjoshi OA,Choudhary S,et al.Design, synthesis, and preclinical evaluation of 4-substituted-5-methyl-furo[2,3-d]pyrimidines as microtubule targeting agents that are effective against multidrug resistant cancer cells[J].J Med Chem,2016,59(12):5752-5765. |
[18]
|
Philchenkov AA,Zavelevich MP,Tryndyak VP,et al.Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells[J].Cancer Biol Ther,2015,16(12):1820-1829. |
[19]
|
Gan PP,McCarroll JA,Po'uha ST,et al.Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaⅢ-tubulin[J].Mol Cancer Ther,2010,9(5):1339-1348. |
[20]
|
Lu Y,Chen J,Xiao M,et al.An overview of tubulin inhibitors that interact with the colchicine binding site[J].Pharm Res,2012,29(11):2943-2971. |
[21]
|
Chamberlain MC,Grimm S,Phuphanich S,et al.A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC)[J].J Neurooncol,2014,118(2):335-343. |
[22]
|
Kasibhatla S,Baichwal V,Cai SX,et al.MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps[J].Cancer Res,2007,67(12):5865-5871. |
[23]
|
Subbiah IM,Lenihan DJ,Tsimberidou AM.Cardiovascular toxicity profiles of vascular-disrupting agents[J].Oncologist,2011,16(8):1120-1130. |
[24]
|
Mahal K,Resch M,Ficner R,et al.Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels[J].ChemMedChem,2014,9(4):847-854. |
[25]
|
Wang XF,Guan F,Ohkoshi E,et al.Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site[J].J Med Chem,2014,57(4):1390-1402. |
[26]
|
Gangjee A,Zhao Y,Raghavan S,et al.Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents[J].J Med Chem,2013,56(17):6829-6844. |
[27]
|
Cao D,Liu Y,Yan W,et al.Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: A novel class of potent tubulin polymerization inhibitors[J].J Med Chem,2016,59(12):5721-5739. |
[28]
|
Zhou B,Xing C.Diverse molecular targets for chalcones with varied bioactivities[J].Med Chem (Los Angeles),2015,5(8):388-404. |
[29]
|
Gwaltney SL,Imade HM,Barr KJ,et al.Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents[J].Bioorg Med Chem Lett,2001,11(7):871-874. |
[30]
|
Romagnoli R,Baraldi PG,Brancale A,et al.Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents[J].J Med Chem,2011,54(14):5144-5153. |
[31]
|
Schobert R,Biersack B,Dietrich A,et al.4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin: A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model[J].J Med Chem,2010,53(18):6595-6602. |
[32]
|
Nathwani SM,Hughes L,Greene LM,et al.Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro[J].Oncol Rep,2013,29(2):585-594. |
[33]
|
Cai D,Qiu Z,Yao W,et al.YSL-12,a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo[J].Cancer Chemother Pharmacol,2016,77(6):1217-1229. |
[34]
|
Mahal K,Biersack B,Schruefer S,et al.Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors[J].Eur J Med Chem,2016,118:9-20. |
[35]
|
La Regina G,Bai R,Rensen W,et al.Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability[J].J Med Chem,2011,54(24):8394-8406. |
[36]
|
An B,Zhang S,Yan J,et al.Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors[J].Org Biomol Chem,2017,15(4):852-862. |
[37]
|
Romagnoli R,Baraldi PG,Salvador MK,et al.Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents[J].J Med Chem,2012,55(11):5433-5445. |
[38]
|
Hwang DJ,Wang J,Li W,et al.Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents[J].ACS Med Chem Lett,2015,6(9):993-997. |
[39]
|
Romagnoli R,Baraldi PG,Salvador MK,et al.Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents[J].J Med Chem,2013,56(6):2606-2618. |
[40]
|
Wang X,Wu E,Wu J,et al.An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells[J].PLoS ONE,2013,8(6):e65686. |
[41]
|
Romagnoli R,Baraldi PG,Salvador MK,et al.Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles[J].J Med Chem,2014,57(15):6795-6808. |
[42]
|
Zhou B,Yu X,Zhuang C,et al.Unambiguous identification of beta-tubulin as the direct cellular target responsible for the cytotoxicity of chalcone by photoaffinity labeling[J].Chem Med Chem,2016,11(13):1436-1445. |
[43]
|
Yang Z,Wu W,Wang J,et al.Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors[J].J Med Chem,2014,57(19):7977-7989. |
[44]
|
Wang G,Li C,He L,et al.Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents[J].Bioorg Med Chem,2014,22(7):2060-2079. |
[45]
|
Zhu C,Zuo Y,Wang R,et al.Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence[J].J Med Chem,2014,57(15):6364-6382. |
[46]
|
Yan J,Chen J,Zhang S,et al.Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo[J].J Med Chem,2016,59(11):5264-5283. |
[47]
|
Aoyama A,Katayama R,Oh-Hara T,et al.Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance[J].Mol Cancer Ther,2014,13(12):2978-2990. |
[48]
|
Eurtivong C,Semenov V,Semenova M,et al.3-Amino-thieno[2,3-b]pyridines as microtubule-destabilising agents: Molecular modelling and biological evaluation in the sea urchin embryo and human cancer cells[J].Bioorg Med Chem,2017,25(2):658-664. |
[49]
|
Zheng YB,Gong JH,Liu XJ,et al.A Novel nitrobenzoate microtubule inhibitor that overcomes multidrug resistance exhibits antitumor activity[J].Sci Rep,2016,6:31472. |
[50]
|
Nakagawa-Goto K,Oda A,Hamel E,et al.Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring[J].J Med Chem,2015,58(5):2378-2389. |
[51]
|
Lee WH,Liu HE,Chang JY,et al.MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells[J].Pharmacology,2013,92(1-2):90-98. |